Gland Pharma Ltd approves Q2 and H1 FY27 results, with Q2 consolidated revenue of ₹18,335.88 million, up 23% year-on-year
- Q2 EBITDA margin was 26%; net profit was ₹2,907.56 million, up 58% year-on-year and down 8% sequentially.
- No exceptional items were reported.
- Deloitte issued unmodified limited-review reports, noting reliance on management-certified information for two immaterial subsidiaries.
- The company also released a press release and investor presentation.
